AAO

Longer treatment intervals possible with 8 mg aflibercept in DME

Data from the ongoing pivotal PHOTON trial presented at AAO 2022 demonstrated that vision was maintained at longer injection intervals with 8 mg intravitreal aflibercept in patients with diabetic macular edema. In this multi-center randomized, double-masked study, patients with DME were randomized 1:2:1 to receive aflibercept 2 mg every 8...